News
News
Exactech Initiates Multi-Center Clinical Trial for New Cartilage Regeneration Technology
December 19, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials announced today it has initiated a prospective, randomized, multi-center, clinical trial to evaluate the safety and effectiveness of a new cartilage repair technology.
Exactech Continues to Expand Spine Portfolio with Comprehensive Solution to Posterior Cervical Fusion
GAINESVILLE, FL – Dec 08, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced the full market launch of its Gibralt® spinal system at the Cervical Spine Research Society Annual Meeting this week.
Exactech Announces Agreement with U.S. Attorney’s Office. Voluntarily Extends Term of Deferred Prosecution Agreement for Three Months
GAINESVILLE, Fla. – December 07, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it agreed to enter into an amendment to its Deferred Prosecution Agreement (DPA) with the United States Attorney’s Office for the District of New Jersey (USAO) that extends the term of the DPA for three months, ending on March 8, 2012.
Exactech Q3 Revenue Up 13% to $47.3M Driven by Robust International Growth. Net Income $1.3M or $0.10 EPS
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $47.3 million for the third quarter of 2011, a 13% increase over $42.0 million in the third quarter of 2010.
Exactech Schedules Third Quarter 2011 Earnings Release and Conference Call
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its third quarter 2011 financial results on November 1, 2011. A copy of the earnings release will be available at http://www.hawkassociates.com.
Exactech CEO Dr. Bill Petty appeared on CNBC’s Kudlow Report on Monday, Oct. 17
Exactech CEO Dr. Bill Petty was interviewed for the Kudlow Report on Monday, Oct. 17. Exactech was highlighted as a middle market company that is managing better than many in this difficult economic climate. Dr. Petty answered questions about Exactech’s performance and the potential impact of proposed healthcare reform initiatives on the company, its customers and ultimately patients.
Exactech Introduces New Material, Efficient Approach for Acetabular Reconstruction
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, reported today the first implantations of its new porous metal acetabular system and novel surgical technique designed to improve the initial stability and long-term biological fixation of hip replacement implants.
Exactech To Present at Canaccord Genuity Investor Conference
GAINESVILLE, Fla. – August 9, 2011 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials will present at the 2011 Canaccord Genuity Growth Conference in Boston on August 11.
Arthritis Patient Helped Create Innovative Knee Implant That Restored His Active Lifestyle
GAINESVILLE, Fla. (Monday, Aug. 8) – Kevin Hindle, a 47-year-old manufacturing engineer at Exactech, Inc., a global orthopaedic device company, regained his active lifestyle with an innovative new knee implant that he helped develop.
Exactech Q2 Revenue Up 9% to $51.7M, Net Income $2.7M, EPS $0.21 Driven by Strong International Growth
GAINESVILLE, Fla. – August 2, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $51.7 million for the second quarter of 2011, a 9% increase over $47.6 million in the second quarter of 2010. Net income decreased 9% to $2.7 million, or $0.21 per diluted share, compared to $3.0 million, or $0.23 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding Health Care Professional (HCP) compliance expenses of $1.5 million related to the Department of Justice (DOJ) settlement, increased 13% to $3.7 million or $0.28 EPS.
Exactech Schedules Second Quarter 2011 Earnings Release and Conference Call
GAINESVILLE, Fla. – July 20, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its second quarter 2011 financial results on August 2, 2011. A copy of the earnings release will be available at http://www.hawkassociates.com.
Exactech Continues to Expand Spine Portfolio Through First Internally-Developed Product
GAINESVILLE, Fla. – May 31, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company’s Exactech Spine division has launched the Proliant™ Polyaxial Pedicle Screw System for orthopaedic and neurosurgeons. This product launch represents the first spinal system developed in-house by Exactech. The company established its spinal division with two acquisitions over the past three years.
Exactech Q1 Revenue Up 9% to $53.4M, Net Income $3.0M With Strong Performance in Hip and Extremity Products
GAINESVILLE, Fla. – May 3, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $53.4 million for the first quarter of 2011, a 9% increase over $49.1 million in the first quarter of 2010. Net income was $3.0 million, or $0.22 per diluted share, compared to $3.3 million, or $0.25 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $1.3 million related to ongoing compliance and monitoring costs associated with the Department of Justice (DOJ) settlement in December 2010, was $3.8 million or $0.28 EPS.
Exactech Announces Full Market Release of the Equinoxe® Shoulder Fracture Plate
GAINESVILLE, Fla. – April 28, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it is fully launching the Equinoxe® Fx Plate, the latest addition to Exactech’s fast-growing Equinoxe® Platform Shoulder System.
Exactech 2010 Revenue Up 7% to $190.5 Million
GAINESVILLE, Fla. – February 28, 2011 -- Exactech, Inc. (Nasdaq: EXAC),a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2010 increased 7% to $190.5 million from $177.3 million in 2009. Diluted earnings per share for the year was $0.80 based on net income of $10.5 million. This compares with net income of $8.3 million or $0.65 diluted EPS a year ago. Net income for 2010 and 2009 included pre-tax legal expenses and compliance costs of $1.3 million and $7.0 million, respectively, related to the Department of Justice (DOJ) inquiry and settlement. Excluding the impact of these expenses, 2010 net income was $11.3 million or $0.86 diluted EPS compared with $13.2 million or $1.03 diluted EPS in 2009.
Exactech Announces Product Lineup for Exhibit at American Academy of Orthopaedic Surgeons Meeting. Management to Present at Investor Conference
GAINESVILLE, Fla. – February 14, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of upcoming investor events.
Exactech Announces 2010 Sales of $190.5 Million and 4th Quarter 2010 Sales of $51.8 Million
GAINESVILLE, Fla. – February 10, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2010 of $51.8 million, an increase of 7% compared to $48.3 million for the fourth quarter of 2009 which will result in full year revenues of $190.5 million, compared to $177.3 million for 2009, a 7% increase. U.S. sales increased 7% during the quarter to $34.5 million and international sales increased 7% during the quarter to $17.3 million. For the full year 2010 U.S. sales increased 8% to $132.0 million and international sales increased 6% to $58.5 million
Stay Connected